In situ TBM immune complex formation has been shown in Heymann nephritis and rarely in membranous glomerulopathy, and TBM deposits have been described in experimental models of chronic serum sickness.

Have you ever heard about a cancer that is "in situ"? There's a reason why it's called that -- and why it's the kind of ...

BostonGene, a leading provider of AI-based molecular and immune profiling solutions today announced the online publication of the manuscript, “Spatial BostonGene Announces Publication in Blood ...

Tumour cells exploit immune checkpoint pathways to diminish T cell activation, thereby hindering the ability of tumour-specific T lymphocytes to mount an attack against them.

CULVER CITY, Calif., February 13, 2025--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunity therapy company, today announced the Medicines and Healthcare products Regulatory Agency (MHRA) has ...

In Situ Vaccine Shows Promise in Using Immune Response to Treat Cancer. February 1, 2018 . Credit: Shutterstock. "This combination of a TLR ligand and an anti-OX40 ...

Treatment turns tumors into cancer vaccine factories Date: April 8, 2019 Source: The Mount Sinai Hospital / Mount Sinai School of Medicine Summary: ...

FORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, May 30, 2025 (GLOBE NEWSWIRE) -- Syncromune ® Inc., a clinical-stage biopharmaceutical company focused on the development of SYNC-T, an in situ ...

In situ vaccination, in which tumors are directly treated with immune stimulating reagents, have powerful potential to improve cancer immunotherapy in a safe and inexpensive manner.

T his past April, Mount Sinai oncologist Joshua Brody and his team announced a clinical trial that delivers immune modulators directly to the tumor environment that stimulate a patient’s immune system ...